Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 2Oligodendroglioma 1Neurocytoma 1Neoplasms, Neuroepithelial 1NF1 1Multiple Myeloma 1Melanoma 1Liposarcoma, Myxoid 1Liposarcoma 1Glioma 1Ganglioneuroma 1Ganglioglioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Astrocytoma 1Advanced Solid Tumor 1

Interventions

Temozolomide 12Bevacizumab 8Carboplatin 6Radiotherapy 5Erlotinib Hydrochloride 5temsirolimus 3Surgical Procedures, Operative 3Irinotecan 3IL13-PE38 3veliparib 2pembrolizumab 2etoposide phosphate 2Vorinostat 2Specimen Handling 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Radiation 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Genetic Therapy 2Everolimus 2Cetuximab 2Carmustine 2Cancer Vaccines 2trastuzumab deruxtecan 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1terameprocol 1sonidegib 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Astrocytoma × mirdametinib × Clear all
NCT04923126 2026-02-04

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
132 enrolled
CNS

Astrocytoma, Ganglioneuroma, Oligodendroglioma, Neoplasms, Neuroepithelial, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡